GSA Capital Partners’s SELLAS Life Sciences SLS Stock Holding History

GSA Capital Partners’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Sell	96,429 -66,861	-41%	-$462K	0.09%	304
2026 Q1	$691K	Sell	163,290 -181,762	-53%	-$813K	0.04%	719
2025 Q4	$1.3M	Sell	345,052 -173,943	-34%	-$338K	0.11%	233
2025 Q3	$836K	Buy	518,995 +92,411	+22%	+$165K	0.07%	519
2025 Q2	$934K	Buy	426,584 +403,857	+1,777%	+$620K	0.07%	507
2025 Q1	$25K	Buy	+22,727	New	+$27K	﹤0.01%	1577
2022 Q1	–	Sell	-10,447	Closed	-$58K	–	1799
2021 Q4	$58K	Buy	+10,447	New	+$79K	0.01%	1344

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSA Capital Partners's SLS Position: Q2 2026 in Review

GSA Capital Partners reduced its SELLAS Life Sciences (SLS) stake by 41% in Q2 2026, selling an estimated $462K and leaving 96,429 shares worth $1.42M. The position accounts for 0.09% of the portfolio, ranked #304.

GSA Capital Partners first reported a position in SLS in Q4 2021 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

GSA Capital Partners held 96,429 shares of SELLAS Life Sciences worth $1.42M as of Q2 2026.
GSA Capital Partners sold 66,861 SELLAS Life Sciences shares in Q2 2026, an estimated $462K.
SELLAS Life Sciences made up 0.09% of GSA Capital Partners's portfolio in Q2 2026, its #304 holding.
GSA Capital Partners first reported a position in SELLAS Life Sciences in Q4 2021 and has held it in 7 quarters since.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.